Malta – Guard services – SPD2/2026/056 - Tender for the Provision of Crowd Control Services for Fairyland 2026 - Malta Tourism Authority

Malta – Landscape gardening services – SERVICES – TENDER FOR THE CLEANING, UPKEEP AND MAINTENANCE OF PUBLIC GARDENS AND SOFT AREAS IN SANTA VENERA USING ENVIRONMENTALLY FRIENDLY PRODUCTS AND PRACTICES

Under the Paul Coverdell Forensic Science Improvements Grant Program, state administering agencies (SAAs) may be eligible and apply for both formula and competitive funds. This NOFO is ONLY for formula funds. An applicant seeking to apply for Coverdell competitive funds (consistent with 34 U.S.C. § 10563(a)(2)) that are available to eligible states and units of local government would need to apply separately under BJA’s FY 2026 Paul Coverdell Forensic Science Improvement—Competitive Grants Program NOFO.

This is a notice of funding opportunity (NOFO) for the BJA FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR) — Competitive Grants Program. This opportunity will increase capacity of states and units of local government with existing crime laboratories to process DNA samples for entry into the Combined DNA Index System (CODIS). The purpose of the CEBR Competitive Program is to maximize the effective utilization of DNA technology to strengthen evidence-based criminal justice responses. The priorities of the CEBR Competitive Program are (1) to use DNA technology to increase the capacity and/or efficiency of publicly funded forensic DNA laboratories to conduct analysis of DNA samples for entry into CODIS and (2) implementing Rapid DNA in the booking station(s) in eligible jurisdictions. The program is designed to fairly and efficiently prioritize jurisdictions facing operational challenges by considering key performance measures reported by publicly funded forensic DNA laboratories. This program is for Competitive funding only. The BJA FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR) — Formula Grants Program for formula funding will post at a later date. Eligible agencies may apply for both Competitive and Formula CEBR Funding.

Czechia – Geotechnical engineering services – Rámcová dohoda na služby GTP menších staveb pozemních komunikací 2026

This is a notice of funding opportunity (NOFO) for the BJA FY 2026 National Center for Veterans Justice. This opportunity will establish a national center to provide specialized support to state, local, and tribal criminal justice agencies; treatment and service providers; courts; corrections systems; and community supervision agencies to effectively support and respond to the needs of veterans across the justice system, improve outcomes, and strengthen public safety. The Center will serve as a one stop shop to address critical gaps in veteran identification, cross-system coordination, and implementation of evidence-based interventions by providing criminal justice professionals with specialized tools, training, and technical assistance on military culture, combat trauma, military sexual trauma (MST), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and other veteran-specific considerations. Providing resources and specialized technical assistance through a centralized location and entity is essential to effectively supporting veterans whose needs require coordination across multiple systems, including criminal justice, Department of Veterans Affairs (VA), behavioral health, and social service systems that operate under distinct legal frameworks and institutional priorities.

The Office of Justice Programs (OJP) is committed to advancing work that furthers the U.S. Department of Justice’s (DOJ) mission to keep our country safe and secure and uphold the rule of law and protect the rights of American citizens. OJP provides federal leadership, funding, and other critical resources to directly support law enforcement, combat violent crime, protect American children, provide services to American crime victims, and address public safety challenges, including human trafficking and the opioid crisis. This NOFO, as authorized by the Bipartisan Safer Communities Act of 2022, will provide funding for the creation or enhancement of state crisis intervention court proceedings and related programs or initiatives, including extreme risk protection order (ERPO) programs, as well as mental health courts, drug courts, and veterans treatment courts.

Malta – Refuse and waste related services – SPD4/2026/032 - Framework Contract for the Provision of Environmentally Friendly Waste Collection Services including the Rental of Skips/Bins for entities within the Active Ageing and Community Care (AACC)

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same target engagement measure; or study the impact of the natural product in a population that is more responsive,

The Genomics Research to Elucidate the Genetics of Rare Diseases:innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying rare genetic disorders. This Notice of Funding Opportunity is intended to stimulate the development and testing of highly innovative experimental or computational approaches for rare disease diagnosis, that have the potential to make transformative improvements to the current state of the art.

This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health.